drugset / Trial / NCT05879822
A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced solid tumors.
Timeline
- Start
- 2023-10-30
- Primary completion
- 2026-07-22
- Completion
- 2026-07-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INCB099280 | Unknown | — | — |